Chronic Hepatitis B Market on Track for Strong Growth, Estimated to Grow at 4.2% CAGR Through 2029

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Chronic Hepatitis B Market Through 2025?
The market size for chronic hepatitis B has consistently expanded over the past several years. The market, currently valued at $3.77 billion in 2024, is expected to ascend to $3.94 billion in 2025, indicating a compound annual growth rate (CAGR) of 4.5%. The historical growth of the market can be credited to the progress in antiviral therapies, amplified government and NGO efforts, advancements in diagnostic methods, an increased incidence of HIV, and heightened public consciousness.

What's the Projected Size of the Global Chronic Hepatitis B Market by 2029?
Predictions indicate a consistent expansion in the chronic hepatitis B market size over the coming years, with an estimated growth to $4.65 billion by 2029, and a compound annual growth rate (CAGR) of 4.2%. This anticipated growth during the projected period can be ascribed to factors such as the development of emerging markets, increased government policies and funding, advancements in diagnostics and screening, growing healthcare spending, progressive strategic alliances and partnerships, an ageing population, and extensive public awareness campaigns. The primary trends expected in the forecasted period are the orientation towards curative treatments, further expansion in emerging markets, improvements in diagnostics and screening, partnerships and collaborations, and heightened emphasis on patient-centered healthcare.

View the full report here:
https://www.thebusinessresearchcompany.com/report/chronic-hepatitis-b-global-market-report

Top Growth Drivers in the Chronic Hepatitis B Industry: What's Accelerating the Market?
The increase in chronic hepatitis B infections is projected to fuel expansion of the chronic hepatitis B virus market. Hepatitis B, a liver infection caused by the hepatitis B virus (HBV), can be avoided through vaccination. The rise in hepatitis B infection rates is largely due to low vaccination levels in low- to middle-income countries, leading to higher transmission rates since sizeable parts of the population are still at risk. This heightened infection rate can amplify the need for diagnostic procedures and various treatments. For example, a Centers for Disease Control and Prevention (CDC) report from June 2024 suggested that elevating global hepatitis B vaccination coverage to 90% and treatment accessibility to 80% could circumvent 26 million new infections and 9 million fatalities related to hepatitis B from 2022 till 2050. As of 2022, there have been 1.2 million new instances of HBV infection. Hence, the high incidence of hepatitis B infection could be a driving force for the chronic hepatitis B virus market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=17112&type=smp

What Trends Will Shape the Chronic Hepatitis B Market Through 2029 and Beyond?
Significant entities in the chronic hepatitis B market are channeling their efforts towards technological innovation, with a particular focus on unique antiviral treatments. These innovative drugs target viral infections, especially resistant strains, inhibiting replication and utilizing sophisticated delivery systems. They are currently undergoing safety and efficacy clinical trials, for example, bepirovirsen intended for chronic hepatitis B. Notably, Global giant GSK plc, a UK-based pharmaceutical and biotechnology multinational, which is highly engaged in research, development, production, and marketing of myriad healthcare products, obtained the U.S. FDA Fast Track designation for bepirovirsen in February 2024. This potential cure, an investigational antisense oligonucleotide (ASO), aims at combating chronic hepatitis B (CHB) by specifically targeting and breaking down the RNA of the hepatitis B virus (HBV), thereby possibly enabling the immune response to take back control of the infection. Positive outcomes were presented in Phase IIb trials, primarily in the B-Clear and B-Sure studies, where the drug demonstrated efficacy in reducing hepatitis B surface antigen (HBsAg) levels and facilitating extended viral suppression.

What Are the Main Segments in the Chronic Hepatitis B Market?
The chronic hepatitis B market covered in this report is segmented -

1) By Drug Class: Antivirals, Immune Modulators
2) By Gender: Male, Female
3) By Distribution Channel: Hospital Pharmacies, Drug Stores And Retail Pharmacies, Online Providers

Subsegments:
1) By Antivirals: Nucleos(T)Ide Analogs (Tenofovir, Entecavir), Interferons (Pegylated Interferon)
2) By Immune Modulators: Immune Checkpoint Inhibitors, Therapeutic Vaccines (HBV Vaccines Under Development)

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=17112&type=smp

Which Top Companies are Driving Growth in the Chronic Hepatitis B Market?
Major companies operating in the chronic hepatitis b market are Pfizer Inc., F Hoffmann-La Roche Ltd, Merck & Co Inc, Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Dynavax Technologies Corporation, Gilead Sciences Inc, Viatris Inc., Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Apotex Corp, Cipla Ltd, Hikma Pharmaceuticals, Lupin Pharmaceuticals Inc, Vir Biotechnology Inc, VBI Vaccines Inc, Shenzhen Hepalink Pharmaceutical Co. Ltd., Accord Healthcare Inc, Par Pharmaceutical Inc, Arrowhead Pharmaceuticals Inc, ViiV Healthcare, Arbutus Biopharma Corporation, Ascentage Pharma, ENYO Pharma, Zydus Pharmaceuticals Inc, Nucorion Pharmaceuticals

Which Regions Will Dominate the Chronic Hepatitis B Market Through 2029?
North America was the largest region in the chronic hepatitis B market in 2023. The regions covered in the chronic hepatitis b market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=17112

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.